source
- New SGO 2026 data show frontline checkpoint inhibitors give 4-year survival boost and almost no relapses after two years in dMMR cancersData presented at the 2026 Society of Gynecologic Oncology meeting highlight the performance of frontline checkpoint inhibitor regimens in patients with deficient mismatch repair (dMMR) cancers. T…
- Four-Year Follow-Up Shows Flat Survival Curves with Frontline Checkpoint Inhibitors in dMMR Endometrial CancerData presented at the 2026 Society of Gynecologic Oncology meeting examined four-year outcomes for patients with dMMR endometrial cancer treated with frontline checkpoint inhibitors. The results s…onclive · 4mo agoPositive readoutPositive